News & Trends - Pharmaceuticals

Australian Commission on Safety and Quality sets out potential COVID-19 treatments

Health Industry Hub | May 21, 2020 |
[Total: 1    Average: 4/5]

The Australian Commission on Safety and Quality in Health Care has released a document summarising re-purposed medicines being investigated to treat COVID-19.

In Australia, on 30 March 2020 it was announced that the Peter Doherty Institute for Infection and Immunity at the University of Melbourne received funding to work on the ASCOT trial. Specifically, lopinavir-ritonavir and hydroxychloroquine will be assessed in patients with COVID-19, admitted to hospital but not to an ICU in 60 hospitals across Australia over the next 2 months.

Work is ongoing to fact check and build on the entries for each medicine. To support this work, the Commission will seek expert opinion from within Australia, for example in pharmacology, epidemiology and virology. The Commission is supported by an extensive network of experts and stakeholders, including peak bodies and universities. The Commission expects to consult with these organisations to assist with development of support resources.

Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

Re-purposed Medicines Being Investigated for COVID-19

Monoclonal antibodies

  1. Tocilizumab (Actemra) – Roche Products, PBS listed
  2. Sarilumab (Kevzara) – Sanofi-Aventis Australia, TGA registered
  3. Meplazumab – Australian sponsor to be determined

Other immunosuppressants

  1. Baricitinib (Olumiant) – Eli Lilly Australia, PBS listed

Antiretrovirals

  1. Lopinavir / ritonavir (Kaletra) – AbbVie, PBS listed
  2. Darunavir / Cobicistat (Prezcobix) – Janssen-Cilag, PBS listed

Antivirals

  1. Remdesivir – Gilead Sciences, not TGA registered
  2. Favipiravir (Avigan) – FUJIFILM Toyama Chemical, not TGA registered
  3. Rintatolimod – AIM ImmunoTech, not TGA registered

Interferons

  1. Interferon beta-1a (Avonex, Rebif) – Biogen Australia and Merck Healthcare, PBS listed
  2. Interferon alpha-2b – Roche Products, not TGA registered
  3. Interferon alpha-1b – MSD Australia and TEVA Pharmaceuticals Australia, not TGA registered
  4. Pegylated interferon lambda (Lambda) – Eiger BioPharmaceuticals, not TGA registered

Antimalarials

  1. Chloroquine (Chlorquin) – Aspen Pharmacare Australia, TGA registered
  2. Hydroxychloroquine (Plaquenil) – Sanofi-Aventis Australia, PBS listed
  3. Mefloquine hydrochloride (Larium) – Pharmaco Australia, TGA registered

Antimicrobials / Antiseptics / Anthelmintics

  1. Azithromycin (Zithromax) – Pfizer Australia, PBS listed
  2. Ciprofloxacin – Bayer Australia, PBS listed
  3. Teicoplanin (Targocid) – Sanofi-Aventis Australia, TGA registered
  4. Povidone-iodine – Sanofi-Aventis Australia, TGA registered
  5. Ivermectin (Stromectol) – MSD Australia, PBS listed
  6. Selamectin – Zoetis Australia, not TGA registered for human use

Peripheral vasodilators

  1. Aviptadil – Biogen Australia, not TGA registered
  2. Sildenafil (Viagra/Revatio) – Pfizer Australia, PBS listed

Others

  1. Convalescent plasma transfusions – from patients who have recovered from viral infections is being investigated for use as a treatment without the occurrence of severe adverse events
  2. Melatonin (Circadin) – RAD Data Australia, TGA registered
  3. Bacillus Calmette-Guérin (BCG) vaccination (ImmuCyst) – Sanofi-Aventis Australia, TGA registered
  4. Chlorpromazine (Largactil) – Sanofi-Aventis Australia, PBS listed
  5. Tranexamic acid – Pfizer Australia, oral form PBS listed

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - COVID-19 wiping out hard-won gains by women in STEM

COVID-19 wiping out hard-won gains by women in STEM

Health Industry Hub | June 1, 2020 |

Hard-won gains for women’s advancement in the science, technology, engineering and maths (STEM) workforce are now at risk of a […]

More


News & Trends - Medical Technology

MedTech News - New agreement to end public hospitals' “harvesting” of privately insured patients

New agreement to end public hospital “harvesting” of privately insured patients

Health Industry Hub | June 1, 2020 |

MedTech News: The new National Health Reform Agreement has the potential to end the practice of public hospitals “harvesting” privately […]

More


News & Trends - Pharmaceuticals

Pharma News - GSK's targeted therapy for asthma gains PBS listing for self-administration delivery

GSK’s targeted therapy for asthma gains PBS listing for self-administration delivery

Health Industry Hub | June 1, 2020 |

Pharma News: From 1 June 2020, GSK Australia’s new pre-filled pen (autoinjector) for the self-administration of its targeted therapy for […]

More


News & Trends - Pharmaceuticals

Pharma News - Major changes to opioid PBS listings effective 1 June

Major changes to opioid PBS listings effective 1 June

Health Industry Hub | June 1, 2020 |

Commencing 1 June 2020, the Pharmaceutical Benefits Scheme (PBS) listings for opioid medicines will change including Tramal (tramadol) and Panadeine […]

More